Citi Downgrades Arcturus Therapeutics (ARCT) to Neutral
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Price: $8.26 +1.47%
Rating Summary:
13 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Rating Summary:
13 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz downgraded Arcturus Therapeutics (NASDAQ: ARCT) from Buy to Neutral with a price target of $12.00.
For an analyst ratings summary and ratings history on Arcturus Therapeutics click here. For more ratings news on Arcturus Therapeutics click here.
Shares of Arcturus Therapeutics closed at $11.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McEwen Copper seeks $1.6b in equity financing for Los Azules - Bloomberg
- Clean Energy Fuels (CLNE) PT Lowered to $2.50 at Raymond James
- TD Cowen Upgrades BRP Inc. (DOOO) to Buy
Create E-mail Alert Related Categories
DowngradesRelated Entities
Citi, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
